On April 1, 2019, the District of Columbia Department of Health Care Finance (DHCF) lifted Medicaid prior authorization requirements for 11 medication assisted treatment (MAT) drugs for addiction disorder. The new policy applies to branded and generic medications to treat opioid use disorder (OUD) and alcohol use disorder (AUD). Medicaid beneficiaries will not be subject to any lifetime limit on access to oral or injectable MAT for treatment of opioid addiction. In late June 2019, the policy was further amended to include acamprosate calcium, the generic for Campral; and disulfiram, the generic for Antabuse. Both medications are for treatment of . . .